Evidence map›Paper›PMID 24695082›Full record

ArticleMolecular pharmacology2014

Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.

Kendra H Oliver, Tammy Jessen, Emily L Crawford, Chang Y Chung, James S Sutcliffe, Ana M Carneiro

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Protein ensembles link genotype to phenotype.PLoS computational biology · 2019
    Review
  3. Article
  4. Article
  5. The Gain-of-Function Integrin β3 Pro33 Variant Alters the Serotonin System in the Mouse Brain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kendra H OliverDepartments of Pharmacology (K.H.O., T.J., C.Y.C., A.M.C.) and Psychiatry, Molecular Physiology, and Biophysics (E.L.C., J.S.S.), Vanderbilt University Medical Center, Nashville, Tennessee.
Tammy Jessen
Emily L Crawford
Chang Y Chung
James S Sutcliffe
Ana M Carneiro
Vanderbilt University Medical Center · US

Funding

Unraveling the Genetic Etiology of AutismR01NS049261 · NINDS · VANDERBILT UNIVERSITY · PI SUTCLIFFE, JAMES S · 2006 to 2010
$2.5M
Regulation of the Serotonin Transporter Function by Integrins in the Mouse BrainR01MH090256 · NIMH · VANDERBILT UNIVERSITY · PI CARNEIRO, ANA MARIN DIAS · 2011 to 2015
$1.9M
NIMH NIH HHS MH090256NIMH NIH HHS R01 MH090256NINDS NIH HHS R01 NS049261NINDS NIH HHS R01-NS049261
6 · The paper itself

Abstract

The plasma-membrane integrin αIIbβ3 (CD41/CD61, GPIIbIIIa) is a major functional receptor in platelets during clotting. A common isoform of integrin β3, Leu33Pro is associated with enhanced platelet function and increased risk for coronary thrombosis and stroke, although these findings remain controversial. To better understand the molecular mechanisms by which this sequence variation modifies platelet function, we produced transgenic knockin mice expressing a Pro32Pro33 integrin β3. Consistent with reports utilizing human platelets, we found significantly reduced bleeding and clotting times, as well as increased in vivo thrombosis, in Pro32Pro33 homozygous mice. These alterations paralleled increases in platelet attachment and spreading onto fibrinogen resulting from enhanced integrin αIIbβ3 function. Activation with protease-activated receptor 4- activating peptide, the main thrombin signaling receptor in mice, showed no significant difference in activation of Pro32Pro33 mice as compared with controls, suggesting that inside-out signaling remains intact. However, under unstimulated conditions, the Pro32Pro33 mutation led to elevated Src phosphorylation, facilitated by increased talin interactions with the β3 cytoplasmic domain, indicating that the αIIbβ3 intracellular domains are primed for activation while the ligand-binding domain remains unchanged. Acute dosing of animals with a Src inhibitor was sufficient to rescue the clotting phenotype in knockin mice to wild-type levels. Together, our data establish that the Pro32Pro33 structural alteration modifies the function of integrin αIIbβ3, priming the integrin for outside-in signaling, ultimately leading to hypercoagulability. Furthermore, our data may support a novel approach to antiplatelet therapy by Src inhibition where hemostasis is maintained while reducing risk for cardiovascular disease.

Indexed as

MutationAmino Acid SequenceAniline CompoundsAnimalsBase SequenceCell AdhesionDNA PrimersHumansIntegrin beta3MiceMolecular Sequence DataNitrilesPhenotypePlatelet Glycoprotein GPIIb-IIIa ComplexPolymerase Chain ReactionProlineAniline CompoundsbosutinibDNA PrimersIntegrin beta3NitrilesPlatelet Glycoprotein GPIIb-IIIa ComplexProlineQuinolinessrc-Family Kinases

Identifiers

PMID24695082
PMCPMC4014669
OpenAlexW2123315394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.